|
Apr 2
|
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
|
|
Mar 29
|
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
|
|
Mar 26
|
Mirum Pharmaceuticals Inc (MIRM) Insider Sells Shares
|
|
Mar 25
|
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
|
|
Mar 15
|
Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use
|
|
Mar 13
|
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
|
|
Jan 16
|
Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer
|
|
Jan 15
|
Should You Invest in Mirum Pharmaceuticals (MIRM)?
|
|
Dec 18
|
Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia
|
|
Nov 30
|
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
|
|
Sep 11
|
Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer
|
|
Sep 9
|
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Sep 6
|
Mirum Pharma (MIRM) Stock Rises 42% Year to Date: Here's Why
|
|
Sep 6
|
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
|
|
May 1
|
VBI Vaccines, Inc. (VBIV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
|
|
Apr 27
|
Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
|
|
Apr 27
|
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
|